ClinicalTrials.gg
RecruitingNCT07393867ARPEGGIOUpdated May 29, 2026

Androgen-responsive POSLUMA-guided Intra-prostatic Boost

A Phase 2 interventional study of PSMA PET/CT and Androgen Deprivation Therapy (ADT) +/- bicalutamide in Intermediate Risk Prostate Cancer, High Risk Prostate Cancer and Prostate Cancer, sponsored by Martin T. King, MD, PhD. Recruiting at 4 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-29.

Sponsored by Martin T. King, MD, PhD · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
23
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 55 studies testing bicalutamide in Prostatic Neoplasms — 5 open to participants now, 9 under way, 3 of them phase 3. bicalutamide · Prostatic Neoplasms.

Planned enrollment
41st of 54
23 · median 53
Started
2026
with 3 others
Phase 2
18 of 55
3 open now
Registered
52nd of 55
by date

Among the 55 studies testing bicalutamide in Prostatic Neoplasms, this one is the 41st largest by planned enrollment of the 54 interventional ones that give a count, is one of 4 that started in 2026, is one of 18 in phase 2, and was the 52nd registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

5 of the 55 studies testing bicalutamide in Prostatic Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About bicalutamide

bicalutamide: first FDA approval 1995 (CASODEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies testing bicalutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

This research study is for men with intermediate- or high-risk prostate cancer who are planning to receive hormone therapy and radiation treatment. The purpose of the study is to see whether a special type of diagnostic imaging done during hormone therapy can help doctors more accurately target remaining cancer with radiation, while avoiding areas that may no longer need extra treatment. All participants will receive standard hormone therapy and radiation therapy, along with three imaging scans, over a six-month period. The information gained from this study may help make prostate cancer radiation treatment more precise and reduce side effects for future patients.

Read the detailed description

Prostate cancer is commonly treated with a combination of hormone therapy and radiation therapy. Hormone therapy, or androgen deprivation therapy (ADT), lowers testosterone levels and often shrinks or weakens prostate cancer before radiation begins. However, after hormone therapy starts, it can become harder for doctors to tell exactly where active cancer remains inside the prostate using standard imaging (typically an MRI). This study is being conducted to determine whether a newer imaging test can better identify which parts of the cancer are still active and may benefit from more focused radiation treatment.

All participants in this study will receive six months of ADT, which is part of standard care for intermediate- and high-risk prostate cancer. In addition, participants will undergo PSMA PET/CT scans, a type of imaging that highlights prostate cancer cells, as well as MRI scans. These scans will be performed at three time-points: before hormone therapy begins, approximately eight weeks after starting hormone therapy (before radiation planning), and again at 24 weeks (at the end of all treatment) to see how the cancer has responded to treatment.

Radiation therapy will begin shortly after the eight-week imaging scan. Participants will receive high-precision radiation (stereotactic body radiation therapy/SBRT) to the prostate over about two weeks. Based on the imaging results, doctors may give an extra "boost" of radiation to small areas that still show signs of active cancer. If the scans show that the cancer has responded well to hormone therapy, some patients may not need this extra boost. This approach is designed to deliver the strongest treatment where it is needed while limiting radiation to healthy tissue in order to minimize side effects.

The main goal of the study is to understand whether doctors can confidently use the mid-treatment PSMA PET/CT scan to guide radiation planning. Researchers will also monitor changes in PSA blood levels, imaging findings, treatment side effects, and patient-reported quality of life, including urinary, bowel, and sexual symptoms. Additionally, doctors participating in the study will provide feedback on how easy or difficult it is to define radiation target areas using the different scans.

Participation in this study lasts about 6 months, and all treatments provided are commonly used in prostate cancer care, with the incorporation of PSMA PET scans being the experimental component. While participants may or may not directly benefit, the results obtained from this study may help improve how radiation therapy is planned and delivered for future patients with prostate cancer, with the goal of maintaining treatment effectiveness while reducing side effects.

03

Conditions studied

  • Intermediate Risk Prostate Cancer
  • High Risk Prostate Cancer
  • Prostate Cancer

Browse trials for

Keywords

  • POSLUMA
  • prostate-specific membrane antigen positron-emission tomography
  • PSMA-PET/CT
  • 18F-flotufolastat-PSMA-PET/CT scan
  • ADT and 18F-flotufolastat-guided focal SBRT microboost
  • androgen deprivation therapy and 18F-flotufolastat-guided focal SBRT microboost
  • neoadjuvant ADT
  • neoadjuvant androgen deprivation therapy
  • neoadjuvant ADT prior to SBRT
  • 18F-flotufolastat-PET/CT scans for intermediate and high risk prostate cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age and older.
  • Eastern Oncology Group Status 0 to 1.
  • Histologic diagnosis of prostate cancer.
  • Prior screening MRI with at least one PI-RADS4 or PI-RADS 5 lesion, obtained within 180 days of screening.
  • NCCN intermediate-risk or high-risk prostate cancer (Appendix B). All patients will be staged by MRI.
  • Prior PSMA PET scan with at least one focal avid lesion greater than background prostate that is concordant with a lesion on MRI, obtained within 180 days of screening.
  • Intention for SBRT (36.25 Gy/5 fraction) with focal boost (up to 50 Gy) to one MRI/PET-concordant lesion34.

Exclusion criteria

Exclusion Criteria:

  • Prior imaging (CT, bone scan, MRI, PSMA-PET/CT) showing nodal or distant disease.
  • Intention to receive treatment intensification with secondary androgen receptor signaling inhibitors or chemotherapy.
  • Clinical T4 disease.
  • Prior ADT.
  • Prior pelvic RT.
  • Prior prostate surgery, including TURP.
  • International prostate symptom score > 20.
  • Prior urethral stricture.
  • Prostate volume > 80 cc on MRI.
  • Hip implants that cause artifacts over the prostate gland.
  • Inability to discontinue anti-coagulation for fiducial marker placement.
  • Active Crohn's disease or scleroderma.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
23 participants (estimated)

Study arms

  • Experimental
    ADT + SBRT + PSMA PET/CT Imaging

    * ADT as prescribed * PSMA PET/CT imaging will be completed at baseline, 8 weeks after ADT start, and at end of treatment * SBRT is administered starting 10 weeks after ADT start

    Diagnostic Test: PSMA PET/CT · Drug: Androgen Deprivation Therapy (ADT) +/- bicalutamide · Radiation: Stereotactic Body Radiation Therapy (SBRT) +/- focal microboost

Interventions

  • Diagnostic testPSMA PET/CT

    PSMA PET/CT is an imaging test that uses a radioactive tracer to highlight prostate cancer cells. Imaging will be performed at baseline, approximately eight weeks after starting ADT, and approximately 24 weeks after starting ADT (end of treatment). These scans are used to guide radiation treatment planning and assess treatment response.

  • DrugAndrogen Deprivation Therapy (ADT) +/- bicalutamide

    Drug page: BicalutamideStudies of BicalutamideBicalutamide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    ADT is used to lower testosterone levels, which can slow or shrink prostate tumors. All participants will receive approximately six months of ADT starting before radiation therapy, using injectable or oral medications. Depending on the type of ADT, participants may also receive daily bicalutamide. Bicalutamide is categorized as an antiandrogen, which means it will block the effects of testosterone and work together with ADT to slow down or shrink prostate cancer.

  • RadiationStereotactic Body Radiation Therapy (SBRT) +/- focal microboost

    SBRT is a form of radiation therapy that delivers precise, high-dose radiation to the prostate over a short period of time. SBRT will be initiated 10 weeks after initiation of ADT and will be delivered in five sessions over two weeks. Based on PSMA PET/CT and MRI findings after initiation of ADT, some participants may receive an optional focal radiation microboost to areas of residual cancer. The microboost, if delivered, will be given during the same SBRT treatment sessions and will be limited by standard safety constraints.

06

What researchers measure

Primary outcomes

  1. Percentage of patients with GTV treatment contours that are highly concordant with GTV-combined interim.

    To evaluate whether \>50% of patients will be treated utilizing GTV contours that are highly concordant with those from interim PET/MR scans (GTV-combined-interim) based on the dice coefficient

    Time frame: 8 weeks from initiation of hormone therapy/before start of radiation therapy

Secondary outcomes

  1. Geometric accuracies of GTV-Combined-Baseline and GTV-combined-interim contours

    The Dice coefficient of GTV-Combined-Baseline contours by the treating physician versus those independently drawn by the principal investigator will be calculated. The Dice coefficient of GTV-Combined-Interim contours by the treating physician versus those independently drawn by the principal investigator will also be calculated.

    Time frame: 8 weeks from initiation of hormone therapy/before start of radiation therapy

  2. PSA response

    The median PSA values at 8-weeks and 24-weeks will be evaluated. The percentage of patients with a PSA≥0.1 ng/mL will be calculated.

    Time frame: 8 weeks from initiation of hormone therapy and 24 weeks from initiation of hormone therapy (end of treatment)

  3. PSMA PET response

    PSMA-PET/CT response at 8-weeks and 24-weeks will be characterized utilizing PSMA PET RECIP 1.0 criteria. * Complete response: Absence of any PSMA uptake at interim PET. * Partial: 30% or greater decrease in PSMA-avid total tumor volume. * Progression: 20% or greater increase in total tumor volume. New PSMA-avid lesions will also count as progression. * Stable disease: Less than 30% decrease or less than 20% increase in total tumor volume.

    Time frame: 8 weeks from initiation of hormone therapy and 24 weeks from initiation of hormone therapy (end of treatment)

  4. MRI ADC contrast ratio

    The ADC contrast ratio at baseline and 8-weeks will be calculated by evaluating the ratio of the mean ADC contrast within GTV-MRI against ADC contrast within a surrounding 2 mm ring.

    Time frame: 8 weeks from initiation of hormone therapy

07

Study locations

2 of 4 sites recruiting
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
    Not yet recruiting
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02115, United States
    Not yet recruiting
  • Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center
    Milford, Massachusetts 01757, United States
    Recruiting
  • Dana-Farber/Brigham and Women's Cancer Center in Clinical Affiliation with South Shore Hospital
    Weymouth, Massachusetts 02190, United States
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Dec 2026, 7 months after the start.

Of 613 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 86. This study's planned 7 months is below that.

Counting every sponsor, half of 727 studies reached it within 53 months; a quarter within 34 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2026
First posted
Feb 6, 2026
StartActual
Apr 29, 2026
Primary completionEst.
Dec 15, 2026
CompletionEst.
Dec 15, 2027
Last update
May 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07393867
Lead sponsor
Martin T. King, MD, PhD
Collaborators
Blue Earth Diagnostics, Dana-Farber/Brigham and Women's Cancer Center
Responsible party
Martin T. King, MD, PhD (Director, Brachytherapy Clinical Operations, Associate Professor of Radiation Oncology, Harvard Medical School, Brigham and Women's Hospital) — Sponsor-investigator
First posted
Feb 6, 2026
Start date
Apr 29, 2026
Primary completion
Dec 15, 2026 (estimated)
Completion
Dec 15, 2027 (estimated)
Last update
May 29, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bicalutamide

Start the discussion